Review
Copyright ©2010 Baishideng. All rights reserved.
World J Gastrointest Pathophysiol. Jun 15, 2010; 1(2): 85-90
Published online Jun 15, 2010. doi: 10.4291/wjgp.v1.i2.85
Pancreatic secretory trypsin inhibitor: More than a trypsin inhibitor
Gai-Ping Wang, Cun-Shuan Xu
Gai-Ping Wang, Cun-Shuan Xu, College of Life Science, Henan Normal University, Xinxiang 453007, Henan Province, China
Gai-Ping Wang, Cun-Shuan Xu, Co-construction Key Laboratory for Cell Differentiation and Regulation, Henan Normal University, Xinxiang 453007, Henan Province, China
Author contributions: Wang GP and Xu CS contributed equally to this work; both were responsible for manuscript writing and revising.
Supported by the National Basic Research 973 Pre-research Program of China, No. 2006CB708506
Correspondence to: Cun-Shuan Xu, Professor, College of Life Science, Henan Normal University, 46 Jianshe East Road, Xinxiang 453007, Henan Province, China. xucs@x263.net
Telephone: +86-373-3326001 Fax: +86-373-3326524
Received: February 4, 2010
Revised: April 15, 2010
Accepted: April 22, 2010
Published online: June 15, 2010
Abstract

Kazal-type serine protease inhibitor is one of the most important and widely distributed protease inhibitor families. Pancreatic secretory trypsin inhibitor (PSTI), also known as serine protease inhibitor Kazal type I(SPINK1), binds rapidly to trypsin, inhibits its activity and is likely to protect the pancreas from prematurely activated trypsinogen. Therefore, it is an important factor in the onset of pancreatitis. Recent studies found that PSTI/SPINK1 is also involved in self-regulation of acinar cell phagocytosis, proliferation and growth of a variety of cell lines. In addition, it takes part in the response to inflammatory factor or injury and is highly related to adult type II citrullinemia.

Keywords: Pancreatic secretory trypsin inhibitor/serine protease inhibitor Kazal type I, Pancreatitis, Autophagy, Cell proliferation, Inflammatory factor, Adult-II citrullinemia.